Clinical Trials Browser

Cholangiocarcinoma × sintilimab × 1 year × Clear all

NCT05348811 2026-01-06

HAIC Combined With Donafenib and Sintilimab for Unresectable ICC

Phase 2 Completed

Gastrointestinal

Cholangiocarcinoma